Literature DB >> 8191415

Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure.

M C Ou1, J Kambayashi, T Kawasaki, Y Uemura, K Shinozaki, E Shiba, M Sakon, M Yukawa, T Mori.   

Abstract

A possible role of platelet-activating factor (PAF) in the occurrence of the two septic complications, i.e., disseminated intravascular coagulation (DIC) and multiple organ failure (MOF) was investigated, employing a rabbit model and a novel PAF antagonist E5880. By an instillation of fecal suspension into the common bile duct of the rabbit, manifestations of DIC and MOF were observed with high reproducibility by 9 hours after the septic insult. E5880 was intravenously administered to 12 rabbits for 1 hour after the septic insult at dose of 1 mg/kg (n = 6) or 3mg/kg (n = 6). All the rabbits were subjected to observation of vital signs and serial determination of laboratory tests for 9 hours and then lung, liver and kidney were removed for histological examination. Blood endotoxin level increased significantly by 9 hours after the septic insult. Although administration of E5880 did not affect the endotoxemia, the antagonist attenuated in a dose related manner laboratory manifestation of DIC such as thrombocytopenia and prolonged prothrombin time as well as that of MOF such as increase in serum bilirubin and creatinine level. The beneficial effect of E5880 on MOF was also confirmed by the histological evaluation. These observations indicated that PAF is deeply involved in the occurrence of DIC and MOF due to sepsis and E5880 may be one of the modalities to treat or prevent these two major septic complications.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191415     DOI: 10.1016/0049-3848(94)90101-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  1 in total

1.  Paf. A mediator in search of a disease.

Authors:  B B Vargaftig
Journal:  Clin Rev Allergy       Date:  1994
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.